Intech Biopharm Ltd(TW:6461)
NT$26.20-0.35 (-1.32%)
TW:6461
Intech Biopharm Ltd financials statements
NT$26.20
At close:-0.35 (-1.32%)
Intech Biopharm Ltd (6461) Ratios
Intech Biopharm Ltd Ratios
TW:6461's free cash flow for Q2 2026 was NT$-106.45M. For the 2026 fiscal year, TW:6461's free cash flow was decreased by NT$-13.33M and operating cash flow was NT$-93.12M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.66 | 1.06 | 1.22 | 1.28 | 1.41 |
| Quick Ratio | 1.18 | 0.90 | 1.15 | 1.14 | 1.22 |
| Cash Ratio | 0.07 | 0.51 | 0.14 | 0.17 | 0.68 |
| Solvency Ratio | -0.24 | -0.18 | -0.16 | -0.16 | -0.17 |
| Operating Cash Flow Ratio | -1.48 | -0.70 | -0.36 | -0.51 | -0.62 |
| Short-Term Operating Cash Flow Coverage | -1.87 | -1.08 | -0.44 | -0.72 | -0.95 |
| Net Current Asset Value | NT$ -846.84M | NT$ -1.17B | NT$ -848.20M | NT$ -1.04B | NT$ -807.66M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.51 | 0.60 | 0.53 | 0.55 | 0.44 |
| Debt-to-Equity Ratio | 1.08 | 1.76 | 1.23 | 1.37 | 0.86 |
| Debt-to-Capital Ratio | 0.52 | 0.64 | 0.55 | 0.58 | 0.46 |
| Long-Term Debt-to-Capital Ratio | 0.47 | 0.59 | 0.45 | 0.53 | 0.41 |
| Financial Leverage Ratio | 2.14 | 2.94 | 2.32 | 2.47 | 1.94 |
| Debt Service Coverage Ratio | -1.24 | -0.87 | -0.44 | -0.76 | -0.85 |
| Interest Coverage Ratio | -10.87 | -10.43 | -9.54 | -13.23 | -14.44 |
| Debt to Market Cap | 0.44 | 0.40 | 0.39 | 0.37 | 0.57 |
| Interest Debt Per Share | 13.04 | 17.33 | 19.76 | 19.95 | 18.16 |
| Net Debt to EBITDA | -4.29 | -5.02 | -6.18 | -6.12 | -4.72 |
| Profitability Margins | |||||
| Gross Profit Margin | -111.71% | -396.25% | -634.48% | -622.75% | -306.87% |
| EBIT Margin | -338.99% | -839.76% | -1177.68% | -1289.11% | -725.51% |
| EBITDA Margin | -254.11% | -620.17% | -849.56% | -928.16% | -507.48% |
| Operating Profit Margin | -338.99% | -895.26% | -1239.87% | -1289.11% | -725.51% |
| Pretax Profit Margin | -355.47% | -925.63% | -1307.64% | -1386.55% | -775.74% |
| Net Profit Margin | -361.80% | -925.63% | -1307.64% | -1386.55% | -775.74% |
| Continuous Operations Profit Margin | -361.80% | -925.63% | -1307.64% | -1386.55% | -775.74% |
| Net Income Per EBT | 101.78% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 104.86% | 103.39% | 105.47% | 107.56% | 106.92% |
| Return on Assets (ROA) | -16.55% | -15.37% | -12.47% | -12.86% | -11.60% |
| Return on Equity (ROE) | -35.33% | -45.22% | -28.94% | -31.78% | -22.56% |
| Return on Capital Employed (ROCE) | -17.29% | -17.73% | -14.96% | -14.00% | -12.39% |
| Return on Invested Capital (ROIC) | -15.84% | -15.77% | -12.29% | -12.48% | -11.33% |
| Return on Tangible Assets | -16.58% | -15.39% | -12.49% | -12.88% | -11.62% |
| Earnings Yield | -14.41% | -10.16% | -9.27% | -8.71% | -14.83% |
| Efficiency Ratios | |||||
| Receivables Turnover | 17.13 | 3.43 | 2.20 | 4.96 | 1.69 |
| Payables Turnover | 58.42 | 20.10 | 614.38 | 128.99 | 65.89 |
| Inventory Turnover | 1.95 | 3.09 | 4.57 | 3.30 | 2.54 |
| Fixed Asset Turnover | 0.08 | 0.02 | 0.01 | 0.01 | 0.02 |
| Asset Turnover | 0.05 | 0.02 | 0.01 | 0.01 | 0.01 |
| Working Capital Turnover Ratio | 1.17 | 0.53 | 0.22 | 0.20 | 0.20 |
| Cash Conversion Cycle | 201.81 | 206.32 | 245.07 | 181.39 | 353.84 |
| Days of Sales Outstanding | 21.30 | 106.41 | 165.83 | 73.56 | 215.60 |
| Days of Inventory Outstanding | 186.76 | 118.07 | 79.84 | 110.66 | 143.78 |
| Days of Payables Outstanding | 6.25 | 18.16 | 0.59 | 2.83 | 5.54 |
| Operating Cycle | 208.06 | 224.48 | 245.67 | 184.22 | 359.37 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.85 | -3.17 | -2.75 | -2.65 | -3.11 |
| Free Cash Flow Per Share | -4.54 | -3.69 | -3.15 | -2.81 | -3.44 |
| Dividend Paid and CapEx Coverage Ratio | -5.64 | -6.17 | -6.80 | -17.31 | -9.42 |
| Capital Expenditure Coverage Ratio | -5.64 | -6.17 | -6.80 | -17.31 | -9.42 |
| Operating Cash Flow Coverage Ratio | -0.30 | -0.19 | -0.14 | -0.14 | -0.17 |
| Operating Cash Flow to Sales Ratio | -3.36 | -6.77 | -7.90 | -8.05 | -5.16 |
| Free Cash Flow Yield | -15.75% | -8.63% | -6.43% | -5.35% | -10.90% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.95 | -9.85 | -10.78 | -11.49 | -6.74 |
| Price-to-Sales (P/S) Ratio | 25.11 | 91.12 | 141.00 | 159.13 | 52.31 |
| Price-to-Book (P/B) Ratio | 2.45 | 4.45 | 3.12 | 3.65 | 1.52 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.35 | -11.59 | -15.55 | -18.68 | -9.17 |
| Price-to-Operating Cash Flow Ratio | -7.48 | -13.46 | -17.85 | -19.76 | -10.14 |
| Price-to-Earnings Growth (PEG) Ratio | 1.55 | 2.13 | 30.41 | 4.74 | -0.35 |
| Enterprise Value Multiple | -14.17 | -19.71 | -22.78 | -23.27 | -15.03 |
| Enterprise Value | 3.87B | 4.86B | 5.00B | 5.11B | 2.97B |
| EV to EBITDA | -14.17 | -19.71 | -22.78 | -23.27 | -15.03 |
| EV to Sales | 36.00 | 122.23 | 193.52 | 215.96 | 76.27 |
| EV to Free Cash Flow | -9.11 | -15.54 | -21.34 | -25.36 | -13.37 |
| EV to Operating Cash Flow | -10.72 | -18.06 | -24.50 | -26.82 | -14.79 |
| Tangible Book Value Per Share | 11.69 | 9.55 | 15.65 | 14.31 | 20.66 |
| Shareholders’ Equity Per Share | 11.75 | 9.60 | 15.71 | 14.38 | 20.73 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.15 | 0.47 | 0.35 | 0.33 | 0.60 |
| Net Income Per Share | -4.15 | -4.34 | -4.55 | -4.57 | -4.68 |
| Tax Burden | 1.02 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.05 | 1.10 | 1.11 | 1.08 | 1.07 |
| Research & Development to Revenue | 1.77 | 3.60 | 4.04 | 5.02 | 3.26 |
| SG&A to Revenue | 0.51 | 1.39 | 2.01 | 2.21 | 1.23 |
| Stock-Based Compensation to Revenue | 0.15 | 0.37 | 0.55 | 0.71 | 0.27 |
| Income Quality | 0.94 | 0.73 | 0.60 | 0.58 | 0.66 |
Currency in TWD
